AIToday
Large Language ModelsTop Companies' AI MovesAI Business & IndustryTop Companies AIPublished: Jun 17, 2026, 06:30 JST

Palo Alto, Databricks embed real-time AI threat detection

Palo Alto, Databricks embed real-time AI threat detection

3 Key Points

  1. What happened

    Palo Alto Networks' Prisma AIRS security API is being integrated with Databricks' Unity AI Gateway, a centralized interface for managing AI models and agents. The integration will inspect AI prompts, responses, and tool calls in real time to detect and block threats like prompt injections, data leakage, malware, and malicious URLs.

  2. Why it matters

    As organizations deploy more autonomous AI agents, security teams face a challenge—traditional security tools cannot detect conversational attacks or the risks introduced by AI workflows. This partnership allows security to be enforced at the governance layer without requiring developers to refactor code or install complex agents, removing what the companies call 'security friction' from production deployments.

  3. What to watch

    The integration will log every transaction with detailed security metadata in Strata Cloud Manager, providing an audit trail for regulatory compliance in industries like finance and healthcare. Technical deep-dive sessions are coming soon, with details available on the Databricks blog.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, in your inbox every morning.

Top Companies AIRead Original Article

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.

Questions and answers are published on this page.

Related Articles

Next articleAbbVie stock is trading 12.6% below analyst fair value estimates after releasing nine-year final results from its CLL14 cancer trial, but faces a valuation puzzle as its P/E ratio signals investors are paying a steep premium for earnings growth.